Gamma Medica-Ideas licenses Mayos molecular breast imaging technology
Gamma Medica-Ideas (GM-I) has signed an agreement with Mayo Clinic in Rochester, Minn. to develop and commercialize a suite of molecular breast imaging technologies invented by a team of Mayo physicians and scientists.
The Northridge, Calif.-based GM-I said it will utilize the licensed technology in conjunction with its Lumagem molecular breast imaging system to improve the diagnosis of cancers in women with dense breasts.
“We believe that the combination of GMI’s detector technology and the algorithms and techniques developed at Mayo, will enable us to achieve a significant reduction in the radiation dose required for molecular breast imaging, and increase the diagnostic utility of this technique," said Michael O’Connor, PhD, who headed the Mayo team.
The license also included methods and devices developed at Mayo for combining next generation x-ray tomosynthesis techniques with molecular imaging of the breast, according to GM-I.
The Northridge, Calif.-based GM-I said it will utilize the licensed technology in conjunction with its Lumagem molecular breast imaging system to improve the diagnosis of cancers in women with dense breasts.
“We believe that the combination of GMI’s detector technology and the algorithms and techniques developed at Mayo, will enable us to achieve a significant reduction in the radiation dose required for molecular breast imaging, and increase the diagnostic utility of this technique," said Michael O’Connor, PhD, who headed the Mayo team.
The license also included methods and devices developed at Mayo for combining next generation x-ray tomosynthesis techniques with molecular imaging of the breast, according to GM-I.